DAVENPORT & Co LLC Sells 297 Shares of Zoetis Inc. $ZTS

DAVENPORT & Co LLC trimmed its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 0.7% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 43,361 shares of the company’s stock after selling 297 shares during the quarter. DAVENPORT & Co LLC’s holdings in Zoetis were worth $6,763,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Nova Wealth Management Inc. bought a new position in Zoetis during the first quarter worth about $25,000. 1248 Management LLC acquired a new stake in Zoetis during the first quarter worth about $27,000. Saudi Central Bank acquired a new stake in Zoetis during the first quarter worth about $29,000. Cornerstone Planning Group LLC grew its stake in Zoetis by 79.3% during the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock worth $30,000 after buying an additional 88 shares in the last quarter. Finally, ORG Partners LLC grew its stake in Zoetis by 56.8% during the second quarter. ORG Partners LLC now owns 232 shares of the company’s stock worth $37,000 after buying an additional 84 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Trading Down 1.7%

ZTS opened at $142.91 on Wednesday. The company’s 50 day moving average is $149.52 and its 200-day moving average is $154.82. Zoetis Inc. has a 1-year low of $139.34 and a 1-year high of $196.55. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The company has a market cap of $63.33 billion, a P/E ratio of 24.60, a PEG ratio of 2.33 and a beta of 0.90.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating analysts’ consensus estimates of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. During the same period last year, the company posted $1.56 EPS. The firm’s quarterly revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ZTS. Piper Sandler increased their price objective on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Leerink Partners downgraded shares of Zoetis from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Leerink Partnrs downgraded shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Argus reiterated a “buy” rating and set a $190.00 price objective on shares of Zoetis in a research note on Tuesday, September 9th. Finally, Stifel Nicolaus downgraded shares of Zoetis from a “buy” rating to a “hold” rating and reduced their price target for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Five analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $200.88.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.